Rexahn Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Partnerships
  • Product Pipeline
    • Overview
    • RX-3117
    • RX-5902
    • RX-0301
    • Publications
  • Clinical Trials
    • Overview
    • Metastatic Pancreatic Cancer Clinical Trial
    • Advanced Bladder Cancer Clinical Trial
    • Triple Negative Breast Cancer Clinical Trial
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations
    • Posters
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Posters

News & Media

News & Media

  • Press Releases
  • Presentations
  • Posters
  • Events
RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models

RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models

Apr 2, 2019
Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)

Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)

Apr 1, 2019
The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated β-catenin nuclear translocation

The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated β-catenin nuclear translocation

Apr 1, 2019
Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trial

Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trial

Mar 31, 2019
Results of a Phase 2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma (mRCC)

Results of a Phase 2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma (mRCC)

Feb 16, 2019
Activity of RX-3117, an Oral Antimetabolite Nucleoside, in Subjects with Advanced Urothelial Cancer: Preliminary Results from a Phase IIa Study

Activity of RX-3117, an Oral Antimetabolite Nucleoside, in Subjects with Advanced Urothelial Cancer: Preliminary Results from a Phase IIa Study

Feb 15, 2019
Phase 1/2 Study Of Rx-3117, An Oral Antimetabolite Nucleoside, In Combination With Nab-Paclitaxel (Nab-Pac) As First Line Treatment of Metastatic Pancreatic Cancer (Met-Pc):Preliminary Results

Phase 1/2 Study Of Rx-3117, An Oral Antimetabolite Nucleoside, In Combination With Nab-Paclitaxel (Nab-Pac) As First Line Treatment of Metastatic Pancreatic Cancer (Met-Pc):Preliminary Results

Jan 18, 2019
RX-3117, A Novel, Oral Nucleoside Analog, in Combination with Nab-paclitaxel (NAB-PAC) in First-line Metastatic Pancreatic Cancer (MET-PC): Safety, Tolerability, and Preliminary Responses

RX-3117, A Novel, Oral Nucleoside Analog, in Combination with Nab-paclitaxel (NAB-PAC) in First-line Metastatic Pancreatic Cancer (MET-PC): Safety, Tolerability, and Preliminary Responses

Oct 2, 2018
Preliminary Results From an Ongoing Phase 2a Study of RX-3117, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)

Preliminary Results From an Ongoing Phase 2a Study of RX-3117, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)

Jun 1, 2018
Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)

Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)

Jun 1, 2018
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
Rexahn Pharmaceuticals, Inc.
© 2019 Rexahn Pharmaceuticals, Inc.
All Rights Reserved.
  • About
  • Overview
  • Management Team
  • Board of Directors
  • Contact
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Partnerships
  • Product Pipeline
  • Overview
  • RX-3117
  • RX-5902
  • RX-0301
  • Publications
  • Clinical Trials
  • Overview
  • Metastatic Pancreatic Cancer
  • Advanced Bladder Cancer
  • Triple Negative Breast Cancer
  • Expanded Access Policy
  • News & Media
  • Press Releases
  • Presentations
  • Posters
  • Events
  • Investors
  • Overview
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Contact
Privacy Policy Disclaimer Sitemap